{"task_id": "d64f5bceb00f75e1", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 289/464)", "text": "acks endocarditis\nSystemic Lupus Erythematosus\n279\n\n--- Page 301 ---\nCLINICAL FEATURES (CONT\u2019D)\n\u0002\nRENAL\nproteinuria or active sediment (sens 50%),\nglomerulonephritis\n\u0002 WHO CLASSIFICATION OF LUPUS NEPHRITIS\n\u0002\nNORMAL (class I)\nasymptomatic\n\u0002\nMESANGIAL\nPROLIFERATIVE\n(class\nII)\nmild\nhematuria or proteinuria\n\u0002\nFOCAL PROLIFERATIVE (class III)\nnephritic syn\ndrome, proteinuria\n\u0002\nDIFFUSE PROLIFERATIVE (class IV)\nnephritic\nsyndrome, nephrotic syndrome\n\u0002\nMEMBRANOUS GLOMERULONEPHRITIS (class V)\nnephrotic syndrome\n\u0002\nGLOMERULOSCLEROSIS (class VI)\nuremia\n\u0002\nSEVERITY\nVI >IV >III >V >II >I, consider\naggressive treatment for class III, IV\n\u0002 GI\nmesenteric thrombosis and vasculitis, transa\nminitis/hepatitis. Corticosteroids could increase\nrisk of peptic ulcer disease\n\u0002\nHEMATOLOGIC\nanemia of chronic disease, autoim\nmune\nhemolytic\nanemia,\nlymphopenia,\nthrombocytopenia\n\u0002\nNEUROLOGIC\naseptic meningitis, transverse myeli\ntis, stroke, seizures, organic brain syndrome, psy\nchosis, depression, peripheral neuropathy\n\u0002\nDERMATOLOGIC\nphotosensitivity (sens 50%), malar\nrash (nasolabial folds spared, sens 50%), discoid\nlupus (erythematous papules/plaques with central\nhypopigmentation, atrophic scarring involving\nscalp and exposed skin, sens 25%), mucosal ulcers\n(oral, vaginal, nasal septal), alopecia, livedo reticu\nlaris, palpable purpura, Raynaud\u2019s\nSEROLOGIC\nANA (sens >99%), anti dsDNA (sens\n40%), anti Smith (sens 25%), SSA/Ro, SSB/La, RNP,\nantiphospholipid antibody (sens 40%)\nCONSTITUTIONAL\nSYMPTOMS\nfatigue,\nfever\n(high grade), lymphadenopathy, weight loss, myalgia\nLUPUS EXACERBATIONS\ntypically with fatigue,\narthritis, mucocutaneous, renal, neurologic, and/or\ndermatologic\ninvolvement.\nIndividual\npatients\nusually have a fixed pattern of presentation. Precipi\ntants include UV exposure, medication non adher\nence, infections, and pregnancy. Always consider\nother causes such as infections, medication side\neffects (steroids), and embolisms\nINVESTIGATIONS\nBASIC\n\u0002\nBLOOD TESTS\nCBCD, lytes, urea, Cr, ESR, CRP,\nANA (sensitive), anti dsDNA (specific for SLE),\nC3, C4\n\u0002\nURINE TESTS\nurinalysis, urine protein to Cr ratio\nSPECIAL\n\u0002\nINFLAMMATORY WORKUP\nENA (anti Smith, spc),\nanti Ro/La (especially in pregnancy, associated\nwith neonatal lupus and congenital complete\nINVESTIGATIONS (CONT\u2019D)\nheart block), antiphospholipid antibodies (antic\nardiolipin\nantibodies,\nlupus\nanticoagulant),\ncryoglobulin\n\u0002\nINFECTIOUS\nWORKUP\nserologies\n(Parvovirus,\nHBV, HCV, EBV, CMV)\n\u0002\nARTHROCENTESIS\nw3Cw (Cell count with diff\n[>2000 WBC/mm3], Culture and Gram stain, Crys\ntal. Cannot make definite diagnosis of systemic\nlupus erythematosus from arthrocentesis)\nMANAGEMENT\nSYMPTOM CONTROL\ncutaneous lupus (sunsc\nreen, hydroxychloroquine). Arthritis (NSAIDs, hydro\nxychloroquine, steroids, methotrexate). Nephritis\nand neuritis (steroids, cyclophosphamide, mycophe\nnolate mofetil). Serositis (NSAIDs, steroids). Throm\nbocytopenia (steroids, IVIG, splenectomy). Avoid\nexogenous estrogen\nTREAT UNDERLYING CAUSE\nrituximab\nSPECIFIC ENTITIES\nDRUG INDUCED SYSTEMIC LUPUS\n\u0002\nPATHOPHYSIOLOGY\nsome drugs may trigger pro\nduction of autoantibodies (e.g. ANA) which may\ncause or precipitate drug induced lupus in suscep\ntible individuals\n\u0002\nCAUSES\nprocainamide,\nhydralazine,\nquinidine,\natenolol, anti TNFa (infliximab, etanercept), capto\npril, carbamazepine, chlorpromazine, enalapril,\nethosuximide,\nhydrochlorothiazide,\nisoniazid,\nlithium, methyldopa, minocycline, minoxidil, phe\nnytoin,\nprimidone,\nstatins,\nsulfasalazine,\ntrimethadione\n\u0002\nCLINICAL FEATURES\ncompared to systemic lupus,\ndrug induced lupus has the following features:\nmiddle age presentation, no gender difference,\nno \u2018\u2018blacks,\u2019\u2019 acute onset, less cutaneous, renal,\nneurologic, and hematologic involvement, but\nequal joint, hepatic, and constitutional symptoms.\nUsually anti histone antibody positive, anti Smith\nnegative, anti dsDNA negative and normal com\nplement levels\n\u0002\nTREATMENTS\ndiscontinue\noffending\ndrug\nif\npossible\nRAYNAUD\u2019S PHENOMENON\n\u0002\nPATHOPHYSIOLOGY\nexaggerated vasoconstriction\nto cold, emotional stress, or exercise. Triphasic\nchanges from white to blue to red\n\u0002\nCAUSES\nprimary (isolated Raynaud\u2019s), secondary\n(trauma [Jack hammer, vibrations], rheumatologic\n[SLE, scleroderma, dermatomyositis, polymyositis,\nrheumatoid arthritis, mixed connective tissue\ndisease], drugs [ergots, cocaine, b blockers, bleo\nmycin, vinblastine, interferon], tumors [lymphoma,\n280\nSystemic Lupus Erythematosus", "text_length": 4421, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 289/464)", "type": "chunk", "chunk_index": 288, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.642474", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.643107", "status": "complete", "chunks_added": 3}